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context: Eye-movement training (EMT) can induce altered brain activation and change 
the functionality of saccades with changes of the brain in general.
Objective: To determine if EMT would result in changes in quantitative electroenceph-
alogram (qEEG) and NIH Stroke Scale (NIHSS) in patients suffering from acute middle 
cerebral artery (MCA) infarction. Our hypothesis is that there would be positive changes 
in qEEG and NIHSS after EMT in patients suffering from acute MCA ischemic stroke.
Design: Double-blind randomized controlled trial.
setting and participants: Thirty-four subjects with acute MCA ischemic stroke treated 
at university affiliated hospital intensive care unit.
interventions: Subjects were randomized into a “control” group treated only with 
aspirin (125 mg/day) and a “treatment” group treated with aspirin (125 mg/day) and a 
subject-specific EMT.
Main outcome measures: Delta–alpha ratio, power ratio index, and the brain symme-
try index calculated by qEEG and NIHSS.
results: There was strong statistical and substantive significant improvement in all 
outcome measures for the group of stroke patients undergoing EMT. Such improvement 
was not observed for the “control” group, and there were no adverse effects.
conclusion: The addition of EMT to a MCA ischemic stroke treatment paradigm has 
demonstrated statistically significant changes in outcome measures and is a low cost, 
safe, and effective complement to standard treatment.
Keywords: ischemic stroke, qeeg, nihss scores, eye moment therapy, stroke rehabilitation, saccades
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inTrODUcTiOn
Stroke is one of the leading causes of death in the United States 
and is a major cause of adult disability; although from 2001 
to 2011 the relative rate of stroke death fell by 35.1% and the 
actual number of stroke deaths declined by 21.2%, the number 
of persons suffering from a stroke is still significant (≈795,000 
each year in the United States alone) and its consequences are 
serious (in 2011, stroke caused ≈1 of every 20 deaths in the 
United States) (1). Its etiology is a change in blood flow to a 
specific area of the brain due to ischemia or hemorrhage, and it is 
usually manifested as brain dysfunction with consequent effects 
such as hemiparesis, dysphasia, ataxia, diplopia, or visual field 
loss. Strokes are diagnosed by physical and neurological examina-
tion, with the help of neurological scales specifically developed 
to quantify the impairment caused by a stroke, in particular the 
NIH Stroke Scale (NIHSS). This scale originally consisted of a 
15-item examination (2), then amended to an 11-item examina-
tion (3), scored on a scale from 0 to 2, 3, or 4 depending on the 
item, for a total score ranging from 0 (normal function) to 42 
(severe stroke). Several studies have reported that the baseline 
NIHSS (taken at hospitalization/diagnosis time) is a good predic-
tor of outcome after a stroke (4–7). Diagnostic tools for strokes 
include CT scans (with or without contrast), MRI scans (espe-
cially diffusion-weighted imaging  –  DWI, and with magnetic 
resonance angiography – MRA), Doppler ultrasound, and digital 
subtraction angiography. In particular, for ischemic stroke, MRI 
scans have shown a higher sensitivity and specificity than CT 
scans without contrast (8). Once patients are hospitalized, elec-
troencephalograms (EEG) are used to continuously monitor their 
brain function as well as to drive clinical management, since EEG 
abnormalities are typical manifestation of an ischemic stroke. In 
particular, quantitative electroencephalogram (qEEG) (9) has 
been used for monitoring and formulating prognosis in acute and 
sub-acute ischemic stroke (10). Of all the numerical parameters 
that can be obtained from the qEEG, of particular interest are 
the ratio of mean scalp delta to alpha power [known as the alpha 
delta ratio (ADR), or its inverse the delta alpha ratio (DAR)] (11, 
12), the power ratio index (PRI) of mean “slow” (delta and theta) 
to mean “fast” (alpha and beta) activity (12–14), and the brain 
symmetry index (BSI or mBSI) (15, 16).
Standard treatment plans for patients affected by ischemic 
stroke involve fibrinolytic therapy (administration of recom-
binant tissue-type plasminogen activator  –  rt-PA), antiplatelet 
agents (such as aspirin), and mechanical thrombectomy (removal 
of the clot causing the blood flow obstruction). After the acute 
phase is concluded, the most effective rehabilitation programs 
involve carefully directed, well-focused, repetitive practice to 
relearn skills that are lost when part of the brain is damaged.
Saccades are fast eye movements that allow humans to vol-
untarily very quickly change the direction of gaze. Extensive 
studies have been conducted to characterize the different brain 
and eye mechanisms generating such movements and how 
different pathologies affect them (17). A number of standard 
parameters have been used to characterize saccades: latency or 
reaction time (the time it takes for the eyes to start moving once 
a stimulus is presented), velocity (at how many deg/s the eyes 
move), amplitude (how many degrees the eyes move), and dura-
tion (how much time it takes) (18). All of these eye movements 
can be quantified with diagnostic equipment, such as video-
nystagmography (VNG), but they can be observed at the bedside 
as well. Standardized objective examination of eye movements 
is of great value in the detection and clarification of sub-clinical 
lesions in the central nervous system. Even patients with multiple 
sclerosis (MS) with lesions beyond the primary visual pathway 
have both saccadic latency and smooth pursuit abnormalities 
of oculomotor dysfunction (19). Patients suffering from mild 
closed-head injury also demonstrate prolonged saccadic laten-
cies, and quantitative tests of oculomotor function may provide 
sensitive markers of cerebral dysfunction (20) that can assist and 
direct patient assessment. For instance, a cerebral vascular lesion 
in the right and/or left hemisphere produces a general slowing 
in the saccadic latency and a general reduction in the accuracy 
of saccades with respect to a healthy subject’s performance (21). 
Abnormalities in the control of saccades have been described 
in patients with cerebral pathology (22), suggesting that they 
might be robust biomarkers that could be utilized in guiding and 
interpreting treatment outcomes. Discrepancy in horizontal and 
vertical tilt angle coefficients can cause eye positions to lie on a 
twisted rather than a planar surface, resulting in eye velocities 
that change during a visual saccade (23). The coordination of eye 
movements is dependent upon the non-linear addition of visual 
saccades and the pursuit components of catch-up saccades that 
can be measured to assess function and disability (24). There 
are many variables that can result in different clinical scenarios 
for patients with similar disease states or injuries. For example, 
elderly patients demonstrate an increased latency and decreased 
peak velocity from age-related degenerative changes in the central 
nervous system with diseases of the central nervous system often 
causing saccadic disorders (25). Different disease states and sites 
of neurological injury may affect one component of a visual task 
while not affecting another. Alzheimer’s patients show increased 
latency to initiation of saccades but no difference in their ampli-
tude and velocity when compared to healthy controls (26). We 
have observed slowing of visual saccades and saccadic intrusions 
of visual pursuits in patients with acute middle cerebral artery 
(MCA) infarction. Abnormal saccadic intrusions consisting of 
frequent sporadic horizontal square wave jerks occur in a large 
percentage of patients with acute or chronic focal cerebral lesions 
(27). Low-amplitude cerebral square wave jerks can be detected 
clinically by fundoscopy at the bedside. Reflexive visually guided 
saccade triggering may be facilitated or inhibited by the cerebral 
cortex. Pierrot-Deseilligny and colleagues observed pathology 
of saccades made toward and away from suddenly appearing 
visual targets in patients with limited unilateral cerebral infarc-
tion (28). Different phenomenology of eye movements have 
been observed with lesions of both the right and left cerebral 
hemisphers. For example, ischemic lesions of the left frontal 
eye field (FEF) have been associated with abnormal reflexive 
visually guided saccades (gap and overlap tasks), antisaccades, 
predictive saccades, memory-guided saccades, smooth pursuit, 
and optokinetic nystagmus (29). Eye-movement analysis not only 
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identifies functional lesions but can also act as a biomarker for 
treatment outcomes. Hemispatial neglect affects the ability to 
explore space on the side opposite a brain lesion that is also mir-
rored in abnormal saccadic eye-movement patterns that provide 
a sensitive means to assess the extent of neglect recovery (30). 
Russell and colleagues provided the first evidence for a deficit 
in remapping visual information across saccades underlying 
right-hemisphere constructional apraxia (RHCA) (31). RHCA is 
a common disorder after right parietal stroke, often persisting 
after initial problems such as visuospatial neglect have resolved. 
Concurrent saccade programing is bilaterally impaired with 
extensive right cerebral damage with an inability to produce 
a corrective saccade within 100  ms after the end of a primary 
saccade (32). Visual field defects after striate lesions are associ-
ated with changes in the frontoparietal network underlying the 
cortical control of saccades, but may improve search strategies 
with appropriate training of saccades (33). Nelles and colleagues 
used functional magnetic resonance imaging (fMRI) to study the 
effects of eye-movement training (EMT) on cortical control of 
saccades (34). EMT induced altered brain activation in the striate 
and extrastriate cortex as well as in oculomotor areas and a rela-
tive decrease of activation in the left FEF. The cerebellum plays a 
major role in saccadic adaptation representing a well-established 
model of  sensory–motor plasticity (35). The cerebellum remains 
intact after MCA infarction, while the intraparietal sulcus may be 
the neural substrate for remapping of the visual environment by 
saccadic training (36). But saccade training may not be enough 
in EMT as repetitive contralesional smooth visual pursuit train-
ing has been shown to induce superior, multimodal therapeutic 
effects in mild and severe chronic stroke patients with neglect 
syndrome (37).
Exploratory findings suggest that measurements of saccades, 
smooth pursuit, and vergence are useful in detecting changes 
associated with mild traumatic brain injuries (38), and it is 
reasonable to utilize them in other brain syndromes, including 
stroke. EMT has been used with vestibular rehabilitation in the 
successful treatment of Post-Traumatic Stress Disorder (PTSD) 
in combat veterans after traumatic brain injury (39–41). Dong 
and colleagues evaluated the sensitivity of measuring cognitive 
processing in the ocular motor system as a marker for recovery 
of deficit in post-stroke patients (42). They tested ocular motor 
function and compared outcomes in the NIHSS score, modified 
Rankin Scale (mRS), and standard cognitive function assess-
ments. Ocular motor function was more sensitive in identifying 
cognitive dysfunction and improvement compared with NIHSS or 
mRS. They concluded that ocular motor assessment demonstrates 
cognitive effects of even mild stroke and may provide improved 
quantifiable measurements of cognitive recovery post-stroke. We 
desired to see if EMT might be beneficial in the treatment of acute 
MCA infarction and hypothesized that it would result in positive 
changes of qEEG and NIHSS.
MaTerials anD MeThODs
This study was a single-center, double-blind, randomized 
controlled clinical trial performed at our Institutional Hospital 
Intensive Care Unit and conducted in accordance with the 
Declaration of Helsinki with equipoise. The protocol was 
approved by the ethics committee of our Institution. Written 
informed consent was obtained from every potential par-
ticipant prior to randomization. The effect of traditional stroke 
therapy (aspirin regimen) combined with a subject-specific 
EMT was investigated in subjects affected by MCA stroke, and 
its outcome compared with a “control” group consisting of 
subjects affected by the same pathology and receiving only the 
aspirin regimen. We utilized the DAR, PRI, and BSI calculated 
by qEEG, and NIHSS as outcome measures of intervention.
Participants
Subjects were recruited from patients with acute MCA ischemic 
stroke admitted to our intensive care unit. Patients with a pre-
sumptive diagnosis of acute MCA ischemic stroke were screened 
within 48 h following stroke onset. Investigators verified eligibil-
ity and obtained written informed consent before randomization 
to two groups.
sample size
The planned sample of 17 subjects in each treatment group was 
calculated to give the study 80% power to detect a 30% reduction 
in NIHSS at a 0.05 significance level for a two-sided test. The 
calculations assumed that 20% of participants would be lost to 
follow-up or non-compliant or would die of other causes.
inclusion criteria
Non-disabling ischemic MCA stroke (mRS ≤3):
• Onset within 48 h before randomization.
• No previous history of cerebral strokes and functionally inde-
pendent (mRS of 0 or 1) pre-morbidity.
• Focal neurological deficit of likely atherothrombotic origin 
classified as ischemic stroke by questionnaire/algorithm and 
confirmed as new cerebral infarction consistent with symp-
toms by cranial computed tomography and brain magnetic 
resonance imaging.
• Age >39 years.
• Agreement to participate in this study.
• Written informed consent.
exclusion criteria
• A previous history of cerebral stroke.
• Potential sources of emboli (atrial fibrillation within 30 days 
of stroke, prosthetic cardiac valve, intracardiac thrombus or 
neoplasm, or valvular vegetation).
• Other major neurological illness that would obscure evalua-
tion of recurrent stroke.
• Refractory depression, severe cognitive impairment, alcohol-
ism or other substance abuse.
• General anesthesia or hospital stay of ≥3  days, any type of 
invasive cardiac instrumentation, or endarterectomy, stent 
placement, thrombectomy, or any other endovascular treat-
ment of carotid artery within 30  days prior to admission to 
intensive care unit or scheduled to be performed.
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randomization, intervention, and  
Follow-up
Fifty-seven subjects who had symptoms and signs of acute MCA 
ischemic stroke within the first 48  h of clinical evolution were 
admitted to our intensive care unit. Of these, 34 subjects (age 
43–83 years old) met the inclusion criteria and were enrolled in 
this study. They had no previous history of cerebral strokes and 
were functionally independent (mRS of 0 or 1) pre-morbidity. 
The subject design was reviewed with subjects and/or their fami-
lies who were offered a place in the study once informed consent 
was obtained. Each subject underwent a CT scan study when 
admitted to exclude hemorrhagic strokes, and a second CT study 
was performed after 72  h of stroke onset. The MCA ischemic 
stroke was diagnosed according to clinical history, neurological, 
and imaging exam. All participants consented to be admitted to 
the study and then were randomly assigned to “treatment” and 
“control” groups. The allocation of participants was programed 
by the statistical coordinating center, encrypted, and entered 
into a data entry program installed on a study computer at our 
institution. After computer verification that all eligibility criteria 
had been met, participants were treated according to their groups 
with both groups receiving standard medical care and support 
in the intensive care unit. The “control” group (11 males and 
6 females, age 58 ±  10.7  years) was treated only with aspirin 
(125 mg/day). The “treatment” group (13 males and 4 females, 
age 61.9 ±  11.67  years) received the same aspirin regimen as 
well as subject-specific EMT. Figure 1 illustrates the CONSORT 
diagram showing the flow of participants.
Treatment group intervention
Ipsilateral saccades are generated by the contralateral cerebral 
cortex and we desired to utilize extraocular muscle targets that 
are associated with cerebellar reflexogenic activation in the plane 
of the anterior and posterior canals. This strategy has been used 
with success in the investigation of the treatment of PTSD in 
combat veterans (39, 40). We prepared video targeting of the 
exercises on Apple iPADs using Apple Keynote software with 
a 2 mm red circular ball target on a blue screen background. 
Subjects with left MCA ischemic stroke performed diagonal 
saccades to appearing targets (with a fixation duration of 2  s 
each) using gap paradigm from the lower left to the upper right 
corner of the tablet monitor, followed by smooth pursuit of the 
target from the upper right corner to the lower left. The saccadic 
EMT activates the combination of right superior rectus and left 
inferior oblique muscles that have reflexogenic connections to 
the right cerebellum. Subjects with right MCA ischemic stroke 
performed the same type of EMT along the opposite diagonal of 
the display (lower right to upper left), activating the combination 
of left superior rectus and right inferior oblique muscles that have 
reflexogenic connections to the left cerebellum. This was followed 
by smooth pursuit of the target from the upper left corner to the 
lower right. Each treatment session consisted of three repetitions 
of the saccades/smooth pursuit sequence, and subjects received 
three such treatments a day. Each repetition took ~3 min with 
the entire intervention session taking <15 min with short breaks 
between repetitions.
intervention Both groups
All subjects underwent EEG testing upon admission and 7 days 
afterward. Using a Medicid-05 (I. C. NEURONIC S.L., Zaragoza, 
Spain), with a gain of 20,000, sampling frequency of 200 Hz, filter 
band pass of 0.3–30 Hz with a “notch” filter at 60 Hz. The noise 
level of the EEG recording was 2 μV RMS and the recordings were 
performed at an environmental temperature of ~23°C. Copper 
electrodes coated with silver chloride were placed on the scalp at 
19 monopolar derivations of the International 10/20 System with 
linked ear lobes as a reference. Electrode-skin impedance was 
<10 kΩ. Total time of EEG data collection per session was 330 s. 
Patients were recumbent, awake, and relaxed. For each subject, 24 
artifact free segments of 2.56 s duration were visually selected by 
an expert electroencephalographer and used for the subsequent 
standard qEEG analysis [power spectrum in the delta (<4 Hz), 
theta (4–7 Hz), alpha (7–14 Hz), and beta (14–30 Hz) frequency 
bands] using the Neuronic EEG 6.0 software (I. C. NEURONIC 
S.L., Zaragoza, Spain). A custom script in MATLAB® (The 
MathWorks, Inc., Natick, MA, USA) was used to calculate the 
DAR, the PRI, and the BSI that were used as outcome measures 
for all subjects. The NIHSS was also administered to all subjects 
upon admission and 7 days afterward.
statistical analysis
The statistical analysis of the outcome measures was performed 
using IBM® SPSS® Statistics release 20.0.0 (IBM Corporation, 
Armonk, NY, USA) on the pre–post qEEG measures for both 
“treatment” and “control” groups and on the pre–post NIHSS 
scores. The normality of the distributions of the data was 
verified using Kolmogorov–Smirnov with Lilliefors Significance 
Correction and Shapiro–Wilk tests of normality. Since these data 
were found to be normally distributed, Multivariate General 
Linear Model (M-GLM) analysis was performed to assess the 
presence of differences between the two groups in the pre-
treatment data, i.e., to verify if the two groups were different to 
begin with. The existence of a difference in pre–post changes 
between the “treatment” and “control” groups was investigated 
by performing a Multivariate Repeated Measures General Linear 
Model (M-RM-GLM), with repeated measures being the pre and 
post measures and the factor being the treatment modality. The 
same M-RM-GLM was performed separately on the two groups 
to verify if the two different treatment modalities were able to 
produce statistically significant changes in the outcome measures.
resUlTs
The descriptive statistics for the pre and post outcome measures 
as well as for their paired pre–post changes for the “treatment” 
and “control” groups are reported in Table 1. Table 2 reports the 
results of the statistical analyses performed on the data: to quan-
tify the presence of statistically significant differences between 
the two groups in the pre-treatment data, and in the pre–post 
results between and within groups. Their significance (p value) 
and effect size (calculated as partial eta squared) are also reported 
in the same table. A partial eta squared of 0.02 is considered a 
small effect, 0.13 a medium effect and 0.26 a large effect. Figure 2 
depicts the pre and post DAR and BSI of “treatment” and “control” 
TaBle 1 | Mean, its 95% confidence interval (ci), and standard deviation (sD) of the Pre, Post, and Pre–Post change for the nihss, Dar, Pri, and Bsi 
measures of “treatment” (subjects receiving eMT therapy in conjunction with the standard aspirin regimen) and “control” (subjects receiving only the 
standard aspirin regiment) groups.
Measure group Pre Post Pre–post change
Mean (ci) sD Mean (ci) sD Mean (ci) sD
NIHSS Treatment 2.82 (1.38: 4.26) 3.03 1.44 (0.67: 2.21) 1.63 −0.81 (−1.34: −0.28) 1.11
Control 2.29 (1.66: 2.92) 1.33 1.86 (1.41: 2.31) 0.95 −0.43 (−0.67: −0.18) 0.51
DAR Treatment 1.77 (1.10: 2.44) 1.40 1.40 (0.81: 1.99) 1.24 −0.37 (−0.67: −0.0.07) 0.63
Control 2.48 (2.19: 2.77) 0.60 2.76 (2.46: 3.06) 0.64 0.28 (0.02: 0.54) 0.55
PRI Treatment 2.39 (1.60: 3.18) 1.66 2.17 (1.30: 3.04) 1.82 −0.22 (−0.51: 0.07) 0.61
Control 3.32 (3.09: 3.55) 0.48 3.69 (3.30: 4.08) 0.81 0.37 (−0.04: 0.78) 0.87
BSI Treatment 0.27 (0.22: 0.32) 0.11 0.33 (0.27: 0.39) 0.13 0.06 (0.03: 0.09) 0.06
Control 0.23 (0.22: 0.24) 0.02 0.23 (0.22: 0.24) 0.03 0.00 (−0.02: 0.02) 0.04
TaBle 2 | results of the statistical analyses performed on the data, 
including the question under examination, each considered parameter, 
its significance (p value) and the effect size (calculated as partial eta 
squared).
statistical question Measure significance 
(p value)
effect size 
(partial eta 
squared)
Are the two groups 
significantly different 
pre-treatment?
Multivariate 0.305 0.164
NIHSS # #
DAR # #
PRI # #
BSI # #
Are the pre–post treatment 
changes significantly different 
between the two groups?
Multivariate 0.004*** 0.402
NIHSS 0.162 0.066
DAR 0.003*** 0.243
PRI 0.029 0.141
BSI 0.001*** 0.279
Are the pre–post treatment 
changes in the “control” group 
significant?
Multivariate 0.011* 0.699
NIHSS 0.008** 0.429
DAR 0.055 0.212
PRI 0.098 0.162
BSI 0.774 0.005
Are the pre–post treatment 
changes in the “treatment” 
group significant?
Multivariate 0.008** 0.631
NIHSS 0.037* 0.243
DAR 0.026* 0.272
PRI 0.158 0.121
BSI 0.000*** 0.550
#Value not calculated because multivariate p did not reached required statistical 
significance (p < 0.05).
*Statistical significance p < 0.05.
**Statistical significance p < 0.01.
***Statistical significance p < 0.005.
Bold font means significant values.
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groups. Figure 3 depicts the pre and post PRI and NIHSS scores 
of “treatment” and “control” groups. Figure 4 illustrates using box 
plots the changes pre and post in the DAR, PRI, and BSI for the 
“treatment” group.
Patient Follow-up Data
We have had no patient follow-up data on this preliminary 
study, but have scheduled all subjects for follow-up with repeat 
diagnostics at 1 year and at yearly times after the initial long-term 
follow-up. We will report our outcomes to long-term follow-up 
when they are available.
efficacy of Treatment
The M-GLM analysis on the initial measurements (“pre”) of the 
outcome measurements (first question in Table 2) indicated that 
the “treatment” and “control” groups are not different to begin 
with, with an overall multivariate tests significance of p = 0.305 
(observed power = 0.341). After verifying the sphericity of the data 
using Mauchly’s test of sphericity, the M-RM-GLM analysis on the 
pre/post measures with the group as a factor (second question in 
Table 2, confirmed by Figures 2 and 3) showed that the differences 
in the changes between the two groups are indeed statistically 
significant. Specifically, the multivariate tests showed that the 
changes are different overall with a p = 0.004 and observed power 
of 0.922 and the tests of between-subjects effects and parameter 
estimates showed that the changes in the DAR, PRI, and BSI are 
different between the “treatment” and “control” groups with p of 
0.003, 0.029, and 0.001 and observed power of 0.875, 0.602, and 
0.926 respectively, whereas the NIHSS change is not significantly 
different between the two groups (p = 0.162). The M-RM-GLM 
analysis on the pre and post measures of the “control” group (third 
question in Table 2, confirmed by Figures 2 and 3) showed that 
there is a statistically significant difference in the pre and post 
measurements for this group (p = 0.011 with observed power of 
0.879), but this difference is produced mostly by the change in 
NIHSS, which is the only measure changing significantly with 
p =  0.008 and observed power of 0.823. The same analysis on 
the “treatment” group (fourth question in Table 2, confirmed by 
Figure 4) showed that the pre/post measures are statistically sig-
nificantly different for this group: the multivariate tests show that 
the measures are different overall with a p = 0.008 and observed 
power of 0.882 and the univariate tests and the tests of within-
subjects contrasts show that NIHSS, DAR, and BSI are different 
with p of 0.037, 0.026, and 0.000 and an observed power of 0.568, 
0.633, and 0.985 respectively, whereas the PRI is not different to a 
statistical significance (p = 0.158, observed power of 0.286).
DiscUssiOn
We did not find any published studies that investigated outcome 
measures in the treatment of acute ischemic stroke using the 
NIHSS and electrical brain activity after EMT. Our results show 
that the group of stroke patients undergoing EMT, although not 
initially different from the “control” group, had a significant 
Assessed for eligibility (n=57)
Excluded  (n=23)
Not meeting inclusion criteria (n=23)
Declined to participate (n=0)
Other reasons (n=0)
Analysed  (n=17)
Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to EMT and standard medical 
intervention (n=17)
Received allocated intervention (n=17)
Did not receive allocated intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to standard intervention (n=17)
Received allocated intervention (n=17)
Did not receive allocated intervention (n=0)
Analysed  (n=17)
Excluded from analysis (n=0)
Randomized (n=34)
FigUre 1 | cOnsOrT diagram showing the flow of participants.
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improvement of the electrical brain activity as measured by 
the DAR and BSI qEEG indices. Such improvement was not 
observed for the “control” group. Furthermore, the improve-
ments in all the qEEG indices considered, i.e., DAR, PRI, and 
BSI, were significantly larger in the patients treated with EMT 
than in the controls. We did not investigate a functional rela-
tionship between qEEG findings in this pilot study, but other 
investigators have considered qEEG as a biomarker for neuro-
logical function. Song and colleagues (43) concluded that qEEG 
measures of background rhythm frequency (BRF) and relative 
power in the qEEG theta band are potential predictive biomark-
ers for cognitive impairment in patients with cerebral infarcts. 
These biomarkers may be valuable in the early prediction of 
cognitive impairment in patients with cerebral infarcts. Our 
findings suggest that EMT might change the qEEG and have the 
potential to decrease cognitive impairment in MCA ischemic 
stroke patients. Song and colleagues (43) also demonstrated that 
the risk hazard of developing cognitive impairment was 14 times 
higher for those with low BRF than for those with high BRF 
(p < 0.001). We have found that EMT increases BRF and perhaps 
decreases the risk hazard of developing cognitive impairment. 
Schleiger and colleagues (44) also analyzed correlations between 
post-stroke qEEG indices and cognition-specific functional 
outcome measures. They reported highly significant correlations 
with cognitive outcomes: frontal DAR (ρ = −0.664, p ≤ 0.001) 
and global, relative alpha power (ρ = 0.67, p ≤ 0.001). We have 
demonstrated that EMT changes these qEEG indices and as a 
consequence may have a functional effect specific to cognition-
specific outcomes and clinical decision-making. Other inves-
tigators have utilized electrophysiological measurements to 
identify the potential therapeutic effects of various treatments in 
acute stroke. For example, Liao and colleagues (45) utilized elec-
trophysiology to evaluate neural and vascular responses of the 
rat cortex to peripheral sensory stimulation following ischemic 
insult. They demonstrated neural recovery and the preservation 
of neurovascular function as well as an optimal time window 
of treatment that might result in minimal infarct volume in 
the ischemic hemisphere. Our findings of qEEG changes after 
EMT have led us to postulate that EMT might also be associ-
ated with neural recovery and better functional outcomes. The 
DAR has also been correlated with motor function recovery. 
Zhang and colleagues (46) evaluated the temporal alterations of 
neural activities using EEG from the acute phase to the chronic 
phase, and compared EEG with the degree of post-stroke motor 
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FigUre 2 | Pre and post delta–alpha ratio and brain symmetry index of “treatment” and “control” groups.
function recovery in a rat model of focal ischemic stroke. The 
DAR was found to have the highest correlation coefficients with 
the motor function recovery. The statistically and substantively 
significant qEEG changes that we have reported after EMT 
would suggest that our therapy might be of use in the treatment 
and rehabilitation of motor function. Our study was specific 
to observe whether EMT would result in changes of qEEG 
and NIHSS without measuring other functional neurological 
changes. Other investigators have used similar technology to 
explore the relationship between qEEG global indexes and their 
association with functional outcome after neurorehabilitation 
in stroke patients. Leon-Carrion and colleagues (47) found that 
qEEG indexes and other clinical variables were correlated with 
functional recovery after neurorehabilitation. They suggested 
that the ratio between delta and alpha may play a significant role 
in predicting and monitoring functional rehabilitation outcome. 
We agree, and our findings that EMT changes the DAR suggest 
a functional application in the treatment of stroke along with 
other neurorehabilitation tools. We have demonstrated statisti-
cally significant changes in the NIHSS after EMT. The NIHSS 
offers a reliable approach to capture the true response patterns 
that are associated with function, outcome, and mortality post-
stroke (48).
The addition of simple EMT to a patient’s treatment paradigm 
has demonstrated statistically significant changes in outcome 
measures and is a low cost, safe, and effective complement 
to standard treatment in MCA ischemic stroke. These results 
complement previous studies utilizing EMT discussed in the 
introduction to this report.
limitations
The outcome measures include only the three qEEG parameters 
and the NIHSS. The NIHSS is a scale of stroke severity and does 
not provide any insight as to functional changes. The study would 
have benefited from the inclusion of some functional outcome 
related to the rationale, e.g., change in visual tracking, cognitive 
and functional testing, etc. Other investigators have found that 
the outcomes we have utilized have been associated with func-
tional changes in neurological function. We expect that EMT will 
also be associated with functional changes and improvement of 
outcomes after stroke treatment. We intend to address functional 
outcome measurements in a new randomized controlled study 
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FigUre 3 | Pre and post power ratio index and nihss scores of “treatment” and “control” groups.
FigUre 4 | Box plot comparing pre and post delta–alpha ratio, power 
ratio index, and brain symmetry index for the “treatment” group.
as our present investigation is considered a pilot from which to 
guide and direct future investigations and did not include other 
functional measurements.
aUThOr cOnTriBUTiOns
FC: designed the study and the eye-movement strategies, wrote 
the manuscript, and contributed to the statistical analysis. EO: 
contributed to the study design, reviewed and edited the manu-
script, and contributed to the statistical analysis. GP: contributed 
to the study design, reviewed and edited the manuscript, and 
contributed to the statistical analysis. CW: reviewed and edited 
the manuscript and contributed to the statistical analysis. CM: 
prepared IRB submissions, patient recruitment, and review of 
the manuscript. GE: coordinated subject diagnosis and treat-
ment, and reviewed the manuscript. AP: reviewed and edited the 
manuscript and contributed to subject assignment. JC: reviewed 
the manuscript and contributed to the data collection and com-
pilation. CB: reviewed the manuscript and contributed to subject 
treatment assignments.
FUnDing
We thank the Carrick Institute and Plasticity Brain Centers for 
generously funding this study.
January 2016 | Volume 7 | Article 39
Carrick et al. Eye-Movement Therapy in Acute Ischemic Stroke
Frontiers in Neurology | www.frontiersin.org
reFerences
1. Mozzafarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. 
Heart disease and stroke statistics – 2015 update: a report from the American 
Heart Association. Circulation (2015) 131(4):e29–322.
2. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et  al. 
Measurements of acute cerebral infarction: a clinical examination scale. Stroke 
(1989) 20:864–70. doi:10.1161/01.STR.20.7.871 
3. U.S. Department of Health and Human Services. National Institute of 
Neurological Disorders and Stroke (NINDS). NIH Stroke Scale Training DVD 
(Version 2.0) [DVD]. Bethesda MD, (2007).
4. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, 
et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: 
a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). 
Neurology (1999) 53:126–31. doi:10.1212/WNL.53.1.126 
5. Schlegel D, Kolb SJ, Luciano JM, Tovar JM, Cucchiara BL, Liebeskind DS, et al. 
Utility of the NIH Stroke Scale as a predictor of hospital disposition. Stroke 
(2003) 34:134–7. doi:10.1161/01.STR.0000048217.44714.02 
6. Bang OY, Park HY, Yoon JH, Yeo SH, Kim JW, Lee MA, et al. Predicting the 
long-term outcome after subacute stroke within the middle cerebral artery 
territor. J Clin Neurol (2005) 1:148–58. doi:10.3988/jcn.2005.1.2.148 
7. Jain A, Houten DV, Sheikh L. Retrospective study on National Institutes of 
Health Stroke Scale as a predictor of patient recovery after stroke. J Cardiovasc 
Nurs (2016) 31(1):69–72. doi:10.1097/JCN.0000000000000198 
8. Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA, Demchuk AM, 
et al. Magnetic resonance imaging and computed tomography in emergency 
assessment of patients with suspected acute stroke: a prospective comparison. 
Lancet (2007) 369:293–8. doi:10.1016/S0140-6736(07)60151-2 
9. Hammond DC. The need for individualization in neurofeedback: hetero-
geneity in QEEG patterns associated with diagnoses and symptoms. Appl 
Psychophysiol Biofeedback (2010) 35:31–6. doi:10.1007/s10484-009-9106-1 
10. Finnigan S, van Putten MJ. EEG in ischemic stroke: quantitative EEG can 
uniquely inform (sub-)acute prognoses and clinical management. Clin 
Neurophysiol (2013) 124:10–9. doi:10.1016/j.clinph.2012.07.003 
11. Claassen J, Hirsch LJ, Kreiter KT, Du EY, Connolly ES, Emerson RG, et al. 
Quantitative continuous EEG for detecting delayed cerebral ischemia in 
patients with poor-grade subarachnoid haemorrhage. Clin Neurophysiol 
(2004) 115:2699–710. doi:10.1016/j.clinph.2004.06.017 
12. Finnigan SP, Walsh M, Rose SE, Chalk JB. Quantitative EEG indices of sub-
acute ischemic stroke correlate with clinical outcomes. Clin Neurophysiol 
(2007) 118:2525–32. doi:10.1016/j.clinph.2007.07.021 
13. Nagata K, Gross CE, Kindt GW, Geier JM, Adey GR. Topographic 
electroencephalographic study with power ratio index mapping in 
patients with malignant brain tumors. Neurosurgery (1985) 17:613–9. 
doi:10.1227/00006123-198510000-00014 
14. Nagata K, Tagawa K, Hiroi S, Shishido F, Uemura K. Electroencephalographic 
correlates of blood flow and oxygen metabolism provided by positron emis-
sion tomography in patients with cerebral infarction. Electroencephalogr Clin 
Neurophysiol (1989) 72:16–30. doi:10.1016/0013-4694(89)90027-8 
15. van Putten MJ, Peters JM, Mulder SM, de Haas JA, Bruijninckx CM, Tavy 
DL. A brain symmetry index (BSI) for online EEG monitoring in carotid 
endarterectomy. Clin Neurophysiol (2004) 115:1189–94. doi:10.1016/j.
clinph.2003.12.002 
16. van Putten MJ. The revised brain symmetry index. Clin Neurophysiol (2007) 
118:2362–7. doi:10.1016/j.clinph.2007.07.019 
17. Leigh RJ, Zee DS. The Neurology of Eye Movements. 4th ed. New York, NY: 
Oxford University Press (2006).
18. Baloh RW, Konrad HR, Sills AW, Honrubia V. The saccade velocity test. 
Neurology (1975) 25(11):1071–6. 
19. Reulen JP, Sanders EA, Hogenhuis LA. Eye movement disorders in multiple 
sclerosis and optic neuritis. Brain (1983) 106(Pt 1):121–40. doi:10.1093/
brain/106.1.121 
20. Heitger MH, Anderson TJ, Jones RD, Dalrymple-Alford JC, Frampton CM, 
Ardagh MW. Eye movement and visuomotor arm movement deficits fol-
lowing mild closed head injury. Brain (2004) 127(Pt 3):575–90. doi:10.1093/
brain/awh066 
21. Pitzalis S, Di Russo F. Spatial anisotropy of saccadic latency in normal subjects 
and brain-damaged patients. Cortex (2001) 37(4):475–92. 
22. Williams IM, Ponsford JL, Gibson KL, Mulhall LE, Curran CA, Abel 
LA. Cerebral control of saccades and neuropsychological test results 
after head injury. J Clin Neurosci (1997) 4(2):186–96. doi:10.1016/
S0967-5868(97)90072-2 
23. Thurtell MJ, Joshi AC, Walker MF. Three-dimensional kinematics of 
saccadic and pursuit eye movements in humans: relationship between 
Donders’ and Listing’s laws. Vision Res (2012) 60:7–15. doi:10.1016/j.
visres.2012.02.012 
24. Rahafrooz A, Fallah A, Jafari AH, Bakouie F, Zendehrouh S, Gharibzadeh 
S. Saccadic and smooth pursuit eye movements: computational modeling 
of a common inhibitory mechanism in brainstem. Neurosci Lett (2008) 
448(1):84–9. doi:10.1016/j.neulet.2008.10.019 
25. Schik G, Mohr S, Hofferberth B. Effect of aging on saccadic eye movements to 
visual and auditory targets. Int Tinnitus J (2000) 6(2):154–9. 
26. Bylsma FW, Rasmusson DX, Rebok GW, Keyl PM, Tune L, Brandt J. Changes 
in visual fixation and saccadic eye movements in Alzheimer’s disease. Int J 
Psychophysiol (1995) 19(1):33–40. doi:10.1016/0167-8760(94)00060-R 
27. Sharpe JA, Herishanu YO, White OB. Cerebral square wave jerks. Neurology 
(1982) 32:57–62. doi:10.1212/WNL.32.1.57 
28. Pierrot-Deseilligny C, Rivaud S, Gaymard B, Agid Y. Cortical control of reflex-
ive visually-guided saccades. Brain (1991) 114(Pt 3):1473–85. doi:10.1093/
brain/114.3.1473 
29. Rivaud S, Muri RM, Gaymard B, Vermersch AI, Pierrot-Deseilligny C. Eye 
movement disorders after frontal eye field lesions in humans. Exp Brain Res 
(1994) 102:110–20. doi:10.1007/BF00232443 
30. Olk B, Harvey M, Gilchrist ID. First saccades reveal biases in recovered 
neglect. Neurocase (2002) 8:306–13. doi:10.1093/neucas/8.4.313 
31. Russell C, Deidda C, Malhotra P, Crinion JT, Merola S, Husain M. A deficit 
of spatial remapping in constructional apraxia after right-hemisphere stroke. 
Brain (2010) 133:1239–51. doi:10.1093/brain/awq052 
32. Ptak R, Schnider A, Muri R. Bilateral impairment of concurrent saccade 
programming in hemispatial neglect. Neuropsychologia (2010) 48:880–6. 
doi:10.1016/j.neuropsychologia.2009.11.005 
33. Nelles G, de Greiff A, Pscherer A, Stude P, Forsting M, Hufnagel A, et  al. 
Saccade induced cortical activation in patients with post-stroke visual field 
defects. J Neurol (2007) 254(9):1244–52. doi:10.1007/s00415-007-0511-1 
34. Nelles G, Pscherer A, de Greiff A, Forsting M, Gerhard H, Esser J, et  al. 
Eye-movement training-induced plasticity in patients with post-stroke 
hemianopia. J Neurol (2009) 256(5):726–33. doi:10.1007/s00415-009-5005-x 
35. Alahyane N, Fonteille V, Urquizar C, Salemme R, Nighoghossian N, Pelisson 
D, et al. Separate neural substrates in the human cerebellum for sensory-motor 
adaptation of reactive and of scanning voluntary saccades. Cerebellum (2008) 
7(4):595–601. doi:10.1007/s12311-008-0065-5 
36. Sapir A, Hayes A, Henik A, Danziger S, Rafal R. Parietal lobe lesions disrupt 
saccadic remapping of inhibitory location tagging. J Cogn Neurosci (2004) 
16:503–9. doi:10.1162/089892904323057245 
37. Kerkhoff G, Reinhart S, Ziegler W, Artinger F, Marquardt C, Keller I. Smooth 
pursuit eye movement training promotes recovery from auditory and visual 
neglect: a randomized controlled study. Neurorehabil Neural Repair (2013) 
27(9):789–98. doi:10.1177/1545968313491012 
38. Hunt AW, Mah K, Reed N, Engel L, Keightley M. Oculomotor-based vision 
assessment in mild traumatic brain injury: a systematic review. J Head Trauma 
Rehabil (2015). doi:10.1097/HTR.0000000000000174 
39. Carrick FR, McLellan K, Brock JB, Randall C, Oggero E. Evaluation of the 
effectiveness of a novel brain and vestibular rehabilitation treatment modality 
in PTSD patients who have suffered combat related traumatic brain injuries. 
Front Public Health (2015) 3:15. doi:10.3389/fpubh.2015.00015 
40. Carrick FR, Pagnacco G, McLellan K, Solis R, Shores J, Fredieu A, et al. Short- 
and long-term effectiveness of a subject’s specific novel brain and vestibular 
rehabilitation treatment modality in combat veterans suffering from PTSD. 
Front Public Health (2015) 3:151. doi:10.3389/fpubh.2015.00151 
41. Carrick FR, Pagnacco G, Wright CH, Oggero E. Changes in saccadic eye 
movements produced by novel brain and vestibular rehabilitation therapy. 
Biomed Sci Instrum (2015) 51:9–16. 
42. Dong W, Yan B, Johnson BP, Millist L, Davis S, Fielding J, et  al. Ischaemic 
stroke: the ocular motor system as a sensitive marker for motor and cognitive 
recovery. J Neurol Neurosurg Psychiatry (2013) 84(3):337–41. doi:10.1136/
jnnp-2012-303926 
January 2016 | Volume 7 | Article 310
Carrick et al. Eye-Movement Therapy in Acute Ischemic Stroke
Frontiers in Neurology | www.frontiersin.org
43. Song Y, Zang DW, Jin YY, Wang ZJ, Ni HY, Yin JZ, et al. Background rhythm 
frequency and theta power of quantitative EEG analysis: predictive biomark-
ers for cognitive impairment post-cerebral infarcts. Clin EEG Neurosci (2015) 
46(2):142–6. doi:10.1177/1550059413517492 
44. Schleiger E, Sheikh N, Rowland T, Wong A, Read S, Finnigan S. Frontal EEG 
delta/alpha ratio and screening for post-stroke cognitive deficits: the power 
of four electrodes. Int J Psychophysiol (2014) 94(1):19–24. doi:10.1016/j.
ijpsycho.2014.06.012 
45. Liao LD, Liu YH, Lai HY, Bandla A, Shih YY, Chen YY, et  al. Rescue of 
cortical neurovascular functions during the hyperacute phase of ischemia by 
peripheral sensory stimulation. Neurobiol Dis (2015) 75:53–63. doi:10.1016/j.
nbd.2014.12.022 
46. Zhang SJ, Ke Z, Li L, Yip SP, Tong KY. EEG patterns from acute 
to chronic stroke phases in focal cerebral ischemic rats: correla-
tions with functional recovery. Physiol Meas (2013) 34:423–35. 
doi:10.1088/0967-3334/34/4/423 
47. Leon-Carrion J, Martin-Rodriguez JF, Damas-Lopez J, Barroso y Martin 
JM, Dominguez-Morales MR. Delta-alpha ratio correlates with level of 
recovery after neurorehabilitation in patients with acquired brain injury. Clin 
Neurophysiol (2009) 120:1039–45. doi:10.1016/j.clinph.2009.01.021 
48. Abdul-Rahim AH, Fulton RL, Sucharew H, Kleindorfer D, Khatri P, Broderick 
JP, et al. National Institutes of Health Stroke Scale item profiles as predictor of 
patient outcome: external validation on independent trial data. Stroke (2015) 
46(2):395–400. doi:10.1161/STROKEAHA.114.006837 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Carrick, Oggero, Pagnacco, Wright, Machado, Estrada, Pando, 
Cossio and Beltrán. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License (CC BY). The use, distribution or reproduc-
tion in other forums is permitted, provided the original author(s) or licensor are 
credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
